Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx in Breast Cancer Patients at Risk of Cardiotoxicity
NCT00563953Phase 2Completed
- Sponsor
- SOLTI
- Start
- Sep 2007
- Primary completion
- Feb 2011
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, sponsored by SOLTI. Primary endpoint: Pathological Complete Response. Started Sep 2007; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00563953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00563953.